artifex

I think it’s a fair concern in general but fine in this case since the company almost certainly edited in the lux operon which is one of the most well studied and understood gene switches out there. It and similar pathways have been used in many branches of science for decades. I think the novelty here is just that it’s in a consumer product instead.

He was probably pulling mid-7 figures for the last 3 years, so at this point I’d guess he just has 3 chickens in the backyard of his palace so that he has something to put on his LinkedIn profile.

A couple prices that went up also have come down, but not by as much as they went up.

I wish there was a good way to track this, because you know a bunch of corps are going to be trying to pass the buck (while also keeping it)